Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia

F K Habib, M Ross, R Tate, G D Chisholm

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.
Original languageEnglish
Pages (from-to)137-44
Number of pages8
JournalClinical Endocrinology
Issue number2
Publication statusPublished - 1997


  • 5-alpha reductase inhibitors
  • aged
  • androgens
  • androstenedione
  • dihydrotestosterone
  • double-blind method
  • finasteride
  • humans
  • prostate
  • prostate-specific antigen
  • prostatic hyperplasia
  • testosterone

Cite this